Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 42Leukemia 35Lymphoma 19Myelodysplastic Syndromes 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 13Hodgkin Disease 13Leukemia, Myeloid, Acute 12Multiple Myeloma 11Myeloproliferative Disorders 9Recurrence 8Lymphoma, T-Cell, Peripheral 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell, Marginal Zone 7Burkitt Lymphoma 7Lymphoma, T-Cell, Cutaneous 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6Hematologic Neoplasms 6Congenital Abnormalities 6Waldenstrom Macroglobulinemia 5Sezary Syndrome 5Primary Myelofibrosis 5Neoplasms, Plasma Cell 5Mycosis Fungoides 5Leukemia, Myeloid, Chronic-Phase 5Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 5Anemia, Aplastic 5Myelodysplastic-Myeloproliferative Diseases 4

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 3Alemtuzumab 3fludarabine 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Cytarabine 2Carmustine 2venetoclax 1thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1itacitinib 1ibrutinib 1Tacrolimus 1Mitoxantrone 1Interleukin-15 1INCB039110 1Hematopoietic Stem Cell Transplantation 1GRN163L peptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic, T-Cell × Alemtuzumab × Clear all
NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT02689453 2022-04-29

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
DermatologicLymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01186640 2022-01-05

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

German CLL Study Group

Phase 2 Completed
16 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡